Recent

% | $
Quotes you view appear here for quick access.

ArQule Inc. Message Board

  • dr_strachan dr_strachan May 5, 2010 10:35 PM Flag

    Comparative lung cancer data

    ARQ 197 in combination with erlotinib extends PFS from 9.7 weeks to 16.1 weeks (66% improvement)

    And for non-squamous cell histology (they wouldn't be the first drug to focus on this histology) PFS was extended from 9.7 weeks to 18.9 weeks (94% improvement)

    For those not familiar with NSCLC trials this is a dramatic improvement in a disease that has seen many many drugs fail. By comparison if you look at the ECOG trial that led to Avastin approval in combination with carbo/paclitaxel PFS was improved from 4.5months to 6.2months (a 38% improvement). The absolute numbers for this trial were higher because these patients weren't 2/3rd line.

    Point is the data looks really good

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • A large well designed phase II trial.

      For contrast take a look at the KERX 24 patient phase II that is running like a pump & dump. Haven't done much research into KERX's drug, I do have serious doubts after a quick glance.

      • 2 Replies to cash2go
      • Hey Cash,

        Good to see a familiar name can't recall where but I'm sure we've overlapped on some of these boards before.

        I actually like the KERX drug while the CRC trial was smaller (but more than 24 pts) it nearly tripled PFS. That magnitude improvement counts for something. I also am convinced about the target PI3K/AKT for several reasons not worth going in to here.

        I think your point however about the patient size is an important one. I once heard a presentation at AACR-NCI-EORTC meeting where the presenter claimed he never saw a phase 2 trial that failed (exageration of course). Most ph2 trials are single arm and very few of them are powered to demonstrate anything. One recent example where a stock demonstrated great ph2 results but awful ph3 results was NVLT in lung cancer. Point is that how the ph2 study was conducted means a lot, and it is this very reason that we likely see a bump at the ASCO meeting, since the ins and outs of the ph2 study data won't be scrutinized until that meeting.

      • I owned KERX in the past, but not now. They are over valued. KERX has more than 300m market cap vs ARQL 230m. LOL

 
ARQL
1.45+0.01(+0.69%)Aug 26 4:00 PMEDT